Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)

Launched by UNIVERSITÄT DUISBURG-ESSEN · Jul 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to better understand why certain gastrointestinal stromal tumors (GIST) stop responding to current treatments. GISTs are a type of cancer that affects the digestive system, and while there are medicines that can control the disease for a time, they don’t cure it. The researchers want to use advanced imaging and genetic testing to create a detailed “resistance profile” that shows how the tumors are changing and resisting treatment. This information could help doctors choose more effective treatments, including local therapies targeted to specific tumor areas.

People who might be eligible for this study are adults with advanced GIST who have already tried and not responded well to several standard treatments (like imatinib, sunitinib, regorafenib, and ripretinib). Participants need to have tumors that can be seen on scans and be able to have a biopsy (a small sample of tumor tissue taken). If accepted, participants can expect to have special imaging scans and possibly a biopsy to gather information about their tumors, which will help doctors understand the resistance patterns. This trial is not yet recruiting, and it’s designed to see how practical it is to use these new testing methods in everyday medical care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Advanced gastrointestinal stromal tumors history of exposure and progression or intolerance to imatinib, sunitinib, regorafenib and ripretinib
• • Clinical indication for PET-CT and tumor biopsy (optional) (sarcoma center tumorboard protocol)
• • Age 18 years and older
• • FFPE tumor tissue available
• • Previous imaging studies available (CT/MRI/PET Abdomen, ideally at baseline, best response and progression)
• • ECOG ≤ 2
• • Progressing tumor lesion(s) of which one is accessible for biopsy
• Exclusion Criteria:
• • contraindication for systemic TKI treatment
• • contraindication for contrast-enhanced both CT and MRI imaging.
• • GIST without KIT or PDGFRA mutations
• • pregnant or breastfeeding women
• • patient that - to the investigator's discretion - are not able or willing to comply with the provided protocol and visit schemes